We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

Ofatumumab

From Proteopedia

Revision as of 07:31, 14 December 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Ofatumumab, better known as Arzerra, (3giz)

Drag the structure with the mouse to rotate

Better Known as: Arzerra

  • Marketed By: Genmab & GlaxoSmithKline
  • Major Indication: Chronic Lymphocytic Leukemia
  • Drug Class: Anti-CD20 Monoclonal Antibody
  • Date of FDA Approval: 2009 (2023)
  • 2009 Sales: $3.1 Billion
  • See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

References


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Joel L. Sussman

Retrieved from "http://52.214.119.220/wiki/index.php/Ofatumumab"
Personal tools